Novartis sues to protect bone meds; Pfizer price-fixing suit dismissed;

> Novartis filed a lawsuit in the United States against Israeli generic drugmaker Teva, over patents for its bone disease treatments Zometa and Reclast. Report

> A California appeals court upheld the dismissal of a 2004 lawsuit against Pfizer and 18 other drugmakers, which alleged they conspired to inflate prices to keep cheaper meds from Canada out of the U.S. Report

> Endo Pharmaceuticals and Penwest Pharmaceuticals have sued generic drug maker Impax for patent infringement related to the pain treatment oxymorphone hydrochloride, a.k.a. Opana ER. Report

> Ivax has sued GlaxoSmithKline for patent infringement in Ireland, over various asthma inhalers sold in that country. Report

> The European Commission Tuesday deepened its antitrust investigation in Pfizer's plan to buy several animal health product franchises from Schering-Plough. Report

> A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. Report

> Shares of Chugai, which is controlled by Roche, jumped on the news that FDA staffers had sounded a distinctly positive note about Actemra for rheumatoid arthritis. Actemra report

> Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy--MK-8122--on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and formulation options. Merck report

> Shares of Vanda Pharmaceuticals plunged after the FDA issued a non-approvable letter for its lead therapy, the schizophrenia drug iloperidone. Vanda report

> Amgen issued some eagerly awaited late-stage data on its bone drug denosumab which demonstrated a lower risk of spine and hip fractures among women with osteoporosis. Denosumab report

> Contract research organizations are playing a growing role helping small biotech companies develop early-stage therapeutics, according to a new report from Turner Investment Partners. CRO report

And Finally... Drugs for ED can help cancer treatments better penetrate the brain. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.